ArticleCancer prevention research (Philadelphia, Pa.)2022
One Barrier to Colorectal Cancer Screening Eliminated: On to the Next.
Article in Cancer prevention research (Philadelphia, Pa.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hispanic Patients Reported Factors for Colonoscopy "No-Shows" Despite a Culturally Tailored Patient Navigation Program.Journal of immigrant and minority health · 2025Observational
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer screening is one of the best proven and most cost-effective of all preventive interventions. Screening lowers both incidence and mortality. Bearing some of the costs of colonoscopy, also known as cost-sharing, has been a barrier to completion of colonoscopy, both as a primary screen and as a second test to complete screening after an abnormal initial stool or radiologic screening test. While a newly published model concludes that eliminating cost-sharing for colonoscopy after an initial screen is cost-effective, the desired outcome has already been achieved. The Centers for Medicaid and Medicare Services has announced the plan to eliminate this final out of pocket expense starting in 2023. While this is an important step, many barriers to screening for colorectal cancer and all other cancers remain. Eliminating downstream costs that result from an abnormal screen is a difficult to achieve but important goal. See related article by Fendrick et al., p. 653.
Indexed as
Identifiers
36193658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.